Single-centre retrospective analysis of growth hormone supplementation in IVF patients classified as poor-prognosis.

about

DHEA Supplementation Confers No Additional Benefit to that of Growth Hormone on Pregnancy and Live Birth Rates in IVF Patients Categorized as Poor Prognosis.Individualized controlled ovarian stimulation in expected poor-responders: an update.

P2860

Q49832425-5D3A26F3-74E5-4FE1-8207-554E766213C2 Q52663984-F5BEBCB9-81C4-478F-A6E7-E56C7DECB02B

P2860

Single-centre retrospective analysis of growth hormone supplementation in IVF patients classified as poor-prognosis.

Item

http://www.wikidata.org/entity/Q42376821

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Single-centre retrospective an ...... classified as poor-prognosis.

@en

Single-centre retrospective an ...... classified as poor-prognosis.

@nl

type

Item

label

Single-centre retrospective an ...... classified as poor-prognosis.

@en

Single-centre retrospective an ...... classified as poor-prognosis.

@nl

prefLabel

Single-centre retrospective an ...... classified as poor-prognosis.

@en

Single-centre retrospective an ...... classified as poor-prognosis.

@nl

P1476

Single-centre retrospective an ...... classified as poor-prognosis.

@en

P2093

Anahita Hamidi

http://www.w3.org/2001/XMLSchema#string

John L Yovich

http://www.w3.org/2001/XMLSchema#string

Peter M Hinchliffe

http://www.w3.org/2001/XMLSchema#string

Satvinder S Dhaliwal

http://www.w3.org/2001/XMLSchema#string

P2860

Growth hormone for in vitro fertilization

Gonadotropin-releasing hormone agonist/antagonist conversion with estrogen priming in low responders with prior in vitro fertilization failure.

Growth hormone co-treatment within a GnRH agonist long protocol in patients with poor ovarian response: a prospective, randomized, clinical trial.

PIVET rFSH dosing algorithms for individualized controlled ovarian stimulation enables optimized pregnancy productivity rates and avoidance of ovarian hyperstimulation syndrome

The re-growth of growth hormone in fertility treatment: a critical review.

British Fertility Society Policy and Practice Committee: adjuvants in IVF: evidence for good clinical practice.

Does the addition of growth hormone to the in vitro fertilization/intracytoplasmic sperm injection antagonist protocol improve outcomes in poor responders? A randomized, controlled trial.

ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria.

Specific ranges of anti-Mullerian hormone and antral follicle count correlate to provide a prognostic indicator for IVF outcome.

Mid-luteal serum progesterone concentrations govern implantation rates for cryopreserved embryo transfers conducted under hormone replacement.

P304

e018107

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/BMJOPEN-2017-018107

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Kevin N. Keane

P577

2017-10-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28993395

http://www.w3.org/2001/XMLSchema#string

P932

5640074

http://www.w3.org/2001/XMLSchema#string

Single-centre retrospective analysis of growth hormone supplementation in IVF patients classified as poor-prognosis.

about

P2860

P2860

Single-centre retrospective analysis of growth hormone supplementation in IVF patients classified as poor-prognosis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932